← back to search

Richard N. Fedorak

University of Alberta · CA
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Gut microbiota and health, and Helicobacter pylori-related gastroenterology studies.
h-index
84
citations
38,187
works
605
NIH funding
primary concept
email

Recent publications

Heterogeneity in Definitions of Efficacy and Safety Endpoints for Clinical Trials of Crohn’s Disease: A Systematic Review
Clinical Gastroenterology and Hepatology 2018cited by 53position: middledoi
Clinical, endoscopic and radiographic outcomes with ustekinumab in medically‐refractory Crohn's disease: real world experience from a multicentre cohort
Alimentary Pharmacology & Therapeutics 2017cited by 183position: middledoi
Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection
Open Forum Infectious Diseases 2017cited by 72position: middledoi
Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set
Clinical Gastroenterology and Hepatology 2017cited by 66position: middledoi
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
Gastroenterology 2016cited by 326position: middledoi
The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection
Journal of Hepatology 2015cited by 184position: middledoi
Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease
Alimentary Pharmacology & Therapeutics 2015cited by 110position: middledoi
The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease
Clinical Gastroenterology and Hepatology 2014cited by 227position: firstdoi
HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants
Nature Genetics 2014cited by 189position: middledoi
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
New England Journal of Medicine 2013cited by 2,675position: middledoi
Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
Gastroenterology 2013cited by 330position: middledoi
Environment and the Inflammatory Bowel Diseases
Canadian Journal of Gastroenterology 2013cited by 155position: middledoi
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
Alimentary Pharmacology & Therapeutics 2013cited by 106position: middledoi
A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
Gut 2012cited by 150position: middledoi
Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease
Gastroenterology 2012cited by 54position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Brian G. Feagan · Western University8 papers (2012–2018)Remo Panaccione · Nutrition-Génétique et Exposition aux Risques Environnementaux7 papers (2013–2018)William J. Sandborn · Mirati Therapeutics (United States)6 papers (2012–2018)Geert D’Haens · Vrije Universiteit Amsterdam4 papers (2012–2018)Alain Bitton · McGill University Health Centre3 papers (2013–2014)Levinus A. Dieleman · University of Alberta3 papers (2013–2017)Christopher Ma · University College London3 papers (2017–2018)Brian Bressler · British Columbia Centre on Substance Use3 papers (2012–2013)Subrata Ghosh · Turbo Power Systems (United Kingdom)3 papers (2013–2017)Paul Rutgeerts · KU Leuven3 papers (2012–2013)John K. Marshall · Institute of Ophthalmology2 papers (2013–2014)Gilaad G. Kaplan · Mount Sinai Hospital2 papers (2013–2017)Laurent Peyrin‐Biroulet · Hôpital Lapeyronie2 papers (2017–2018)Claire E. Parker · London Health Sciences Centre2 papers (2017–2018)A. Hillary Steinhart · Lunenfeld-Tanenbaum Research Institute2 papers (2013–2014)Corey A. Siegel · Dartmouth–Hitchcock Medical Center2 papers (2017–2018) · 2 papers (2017–2018) · 2 papers (2017–2018) · 2 papers (2013–2014)Gordon R. Greenberg · University of Toronto2 papers (2013–2013)